Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$42.78 -0.4%	$32.22	$21.97 ▼ $43.97	$2.03B	1.64	535,231 shs	502,276 shs
EYE National Vision	$22.73 -1.0%	$23.71	$9.56 ▼ $25.67	$1.82B	1.27	2.15 million shs	1.28 million shs
KIDS OrthoPediatrics	$19.19 +0.3%	$21.27	$16.59 ▼ $33.14	$479.67M	1.12	191,577 shs	101,235 shs
LQDA Liquidia Technologies	$25.95 -0.5%	$16.30	$8.26 ▼ $26.65	$2.23B	0.14	3.39 million shs	2.84 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	-0.42%	+4.62%	+35.91%	+45.21%	+74.54%
EYE National Vision	-0.96%	+0.40%	-10.30%	+18.26%	+117.51%
KIDS OrthoPediatrics	+0.31%	+1.48%	-14.94%	-16.82%	-24.24%
LQDA Liquidia Technologies	-0.54%	+26.89%	+82.88%	+37.45%	+88.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AORT Artivion	3.3827 of 5 stars	2.5	5.0	0.0	2.5	2.5	1.9
EYE National Vision	2.6264 of 5 stars	2.3	2.0	3.3	3.0	0.0	0.0
KIDS OrthoPediatrics	4.0015 of 5 stars	3.4	1.0	3.9	1.9	3.3	0.6
LQDA Liquidia Technologies	3.5277 of 5 stars	3.5	3.0	0.0	2.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	3.00	Buy	$39.80	-6.97% Downside
EYE National Vision	2.60	Moderate Buy	$24.73	8.79% Upside
KIDS OrthoPediatrics	2.88	Moderate Buy	$34.14	77.92% Upside
LQDA Liquidia Technologies	3.00	Buy	$31.40	21.00% Upside

Current Analyst Ratings Breakdown

Latest KIDS, EYE, AORT, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	LQDA Liquidia Technologies	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$43.00
8/13/2025	AORT Artivion	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$32.00 ➝ $38.80
8/13/2025	LQDA Liquidia Technologies	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$33.00 ➝ $41.00
8/13/2025	LQDA Liquidia Technologies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $31.00
8/12/2025	LQDA Liquidia Technologies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/8/2025	AORT Artivion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/8/2025	KIDS OrthoPediatrics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Outperform ➝ Market Outperform	$50.00 ➝ $35.00
8/8/2025	KIDS OrthoPediatrics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform
8/8/2025	AORT Artivion	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $41.00
8/8/2025	AORT Artivion	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$33.00 ➝ $42.00
8/8/2025	AORT Artivion	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $40.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$388.54M	5.19	$0.83 per share	51.48	$8.90 per share	4.81
EYE National Vision	$1.89B	0.95	$1.62 per share	14.03	$10.74 per share	2.12
KIDS OrthoPediatrics	$220.73M	2.18	N/A	N/A	$14.18 per share	1.35
LQDA Liquidia Technologies	$19.32M	115.62	N/A	N/A	$0.18 per share	144.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	-$13.36M	-$0.42	N/A	85.56	N/A	-4.43%	5.70%	2.29%	N/A
EYE National Vision	-$28.50M	-$0.18	N/A	84.19	2.71	-0.75%	3.56%	1.49%	N/A
KIDS OrthoPediatrics	-$37.82M	-$1.79	N/A	N/A	N/A	-18.92%	-6.36%	-4.69%	N/A
LQDA Liquidia Technologies	-$130.39M	-$1.70	N/A	N/A	N/A	-732.17%	-232.96%	-60.81%	N/A

Latest KIDS, EYE, AORT, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	LQDA Liquidia Technologies	-$0.43	-$0.49	-$0.06	-$0.49	$3.90 million	$8.84 million
8/7/2025	Q2 2025	AORT Artivion	$0.11	$0.24	+$0.13	$0.03	$107.96 million	$112.97 million
8/6/2025	Q2 2025	EYE National Vision	$0.12	$0.18	+$0.06	$0.11	$469.21 million	$486.42 million
8/5/2025	Q2 2025	KIDS OrthoPediatrics	-$0.17	-$0.11	+$0.06	-$0.30	$61.40 million	$61.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
EYE National Vision	N/A	N/A	N/A	N/A	N/A
KIDS OrthoPediatrics	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	0.52	4.78	3.48
EYE National Vision	0.30	0.52	0.31
KIDS OrthoPediatrics	0.27	6.66	3.43
LQDA Liquidia Technologies	9.84	2.49	2.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
EYE National Vision	N/A
KIDS OrthoPediatrics	69.05%
LQDA Liquidia Technologies	64.54%

Insider Ownership

Company	Insider Ownership
AORT Artivion	7.60%
EYE National Vision	2.70%
KIDS OrthoPediatrics	32.70%
LQDA Liquidia Technologies	26.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,600	47.18 million	43.60 million	Optionable
EYE National Vision	13,411	79.20 million	77.06 million	Optionable
KIDS OrthoPediatrics	200	25.07 million	16.88 million	Optionable
LQDA Liquidia Technologies	50	86.09 million	63.28 million	Optionable

KIDS, EYE, AORT, and LQDA Headlines

Recent News About These Companies

Liquidia Technologies (NASDAQ:LQDA) Trading 5.3% Higher Following Analyst Upgrade

3 hours ago | marketbeat.com

Lifesci Capital Has Pessimistic Outlook of LQDA Q3 Earnings

August 16 at 2:15 AM | americanbankingnews.com

Liquidia Technologies (NASDAQ:LQDA) Price Target Raised to $41.00 at Raymond James Financial

August 15 at 9:07 AM | marketbeat.com

Liquidia Technologies (NASDAQ:LQDA) Given New $31.00 Price Target at Wells Fargo & Company

August 15 at 8:44 AM | marketbeat.com

Needham & Company LLC Forecasts Strong Price Appreciation for Liquidia Technologies (NASDAQ:LQDA) Stock

August 15 at 8:44 AM | marketbeat.com

Liquidia Technologies (NASDAQ:LQDA) Price Target Raised to $36.00

August 15 at 2:07 AM | americanbankingnews.com

Liquidia Technologies Sees Unusually High Options Volume (NASDAQ:LQDA)

August 14 at 2:39 AM | americanbankingnews.com

Liquidia Analysts Raise Their Forecasts Following Q2 Results

August 13 at 3:20 PM | benzinga.com

4LQDA : 12 Analysts Have This To Say About Liquidia

August 13 at 3:08 PM | benzinga.com

Liquidia Analysts Raise Their Forecasts Following Q2 Results

August 13 at 2:51 PM | benzinga.com

Stock Traders Buy High Volume of Liquidia Technologies Call Options (NASDAQ:LQDA)

August 13 at 10:52 AM | marketbeat.com

Liquidia Technologies (NASDAQ:LQDA) Announces Quarterly Earnings Results, Misses Expectations By $0.06 EPS

August 13 at 9:26 AM | marketbeat.com

Liquidia Technologies (NASDAQ:LQDA) Reaches New 1-Year High - Here's What Happened

August 13 at 6:21 AM | marketbeat.com

Liquidia Corporation’s Strong Launch of YUTREPIA

August 13 at 5:06 AM | msn.com

Liquidia Technologies, Inc.: Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | finanznachrichten.de

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates

August 12, 2025 | zacks.com

Why Is Liquidia Stock Trading Higher On Tuesday?

August 12, 2025 | benzinga.com

Liquidia Corporation 2025 Q2 - Results - Earnings Call Presentation

August 12, 2025 | seekingalpha.com

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12, 2025 | globenewswire.com

Earnings Preview For Liquidia

August 11, 2025 | benzinga.com

Liquidia: Uncertainty Has Always Been A Buying Opportunity

August 11, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KIDS, EYE, AORT, and LQDA Company Descriptions

Artivion NYSE:AORT

$42.78 -0.17 (-0.40%)

Closing price 08/15/2025 03:58 PM Eastern

Extended Trading

$42.20 -0.58 (-1.34%)

As of 08/15/2025 07:53 PM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

National Vision NASDAQ:EYE

$22.73 -0.22 (-0.96%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$22.73 0.00 (0.00%)

As of 08/15/2025 06:23 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

OrthoPediatrics NASDAQ:KIDS

$19.19 +0.06 (+0.31%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$19.19 0.00 (0.00%)

As of 08/15/2025 05:44 PM Eastern

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Liquidia Technologies NASDAQ:LQDA

$25.95 -0.14 (-0.54%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$25.97 +0.02 (+0.08%)

As of 08/15/2025 06:41 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time